Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC.ADIL · Entity 7742 | Chief Financial Officer | April 07, 2026 | April 09, 2026 |
| Aravive, Inc.ARAV · Entity 114535 | Chief Financial Officer | January 24, 2022 | January 25, 2022 |
| Virpax Pharmaceuticals, Inc.VRPX · Entity 84306 | Chief Financial Officer | January 29, 2024 | January 31, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADIAL PHARMACEUTICALS, INC.
Report date April 07, 2026 · Filed April 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,325 |
Reported balance
After 2026-04-07 transaction · row 1
1 source rowRow 1 · 2026-04-07 · Grant · Acquired 17,325 · Balance 17,325 F1: Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date.
Aravive, Inc.
Report date January 24, 2022 · Filed January 25, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2032-01-24 | Direct | 175,000 |
Reported balance
After 2022-01-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-24 · Grant · Acquired 175,000 · Balance 175,000 F1: These options vest pro rata on a monthly basis over four (4) years commencing on February 24, 2022, the one-month anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest pro rata on a monthly basis over four (4) years commencing on February 24, 2022, the one-month anniversary of the grant date.
Virpax Pharmaceuticals, Inc.
Report date January 29, 2024 · Filed January 31, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.32 · Expires 2034-01-28 | Direct | 112,000 |
Reported balance
After 2024-01-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-29 · Grant · Acquired 112,000 · Balance 112,000 F1: These options vest pro rata on a monthly basis for 36 months commencing one year after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest pro rata on a monthly basis for 36 months commencing one year after the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 07, 2026 Filed Apr 9, 2026 21:00 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantCommon Stock | 17,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-042053 · ownership.xml · nonDerivative · entry 1 Shah Vinay · CIK 0001753078 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,325 F1 · shares: Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:01 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001213900-25-050019 · ownership.xml · derivative · entry 1 Shah Vinay · CIK 0001753078 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2035-05-28 F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025. F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025. Read SEC document |
| November 16, 2024 Filed Nov 18, 2024 21:01 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantStock Option · Derivative | 40,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001213900-24-099632 · ownership.xml · derivative · entry 1 Shah Vinay · CIK 0001753078 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-11-15 F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 21:25 UTC | Virpax Pharmaceuticals, Inc. VRPX · Entity 84306 | GrantStock Option (right to buy) · Derivative | 112,000 | $0.00 Strike: $0.32 | $0.00 |
DisclosureSEC source: 0001213900-24-008459 · ownership.xml · derivative · entry 1 Shah Vinay · CIK 0001753078 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock · 112,000 shares Expires 2034-01-28 F1 · shares: These options vest pro rata on a monthly basis for 36 months commencing one year after the date of grant. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis for 36 months commencing one year after the date of grant. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 20:18 UTC | Virpax Pharmaceuticals, Inc. VRPX · Entity 84306 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001213900-23-050514 · ownership.xml · derivative · entry 1 Shah Vinay · CIK 0001753078 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-06-20 F1 · shares: 25% of the shares subject to the option will vest after 12 months of continuous service, and the remaining 75% of the shares subject to the Option will vest in equal monthly installments over the next 36 months of continuous service Read SEC document |
| June 20, 2023 Filed Aug 16, 2023 21:00 UTC Amendment | Virpax Pharmaceuticals, Inc. VRPX · Entity 84306 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001213900-23-068265 · ownership.xml · derivative · entry 1 Shah Vinay · CIK 0001753078 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-06-20 F1 · shares: 25% of the shares subject to the option will vest after 12 months of continuous service, and the remaining 75% of the shares subject to the Option will vest in equal monthly installments over the next 24 months of continuous service Read SEC document |
| January 24, 2022 Filed Jan 25, 2022 21:05 UTC | Aravive, Inc. ARAV · Entity 114535 | GrantStock Option (Right to buy) · Derivative | 175,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001437749-22-001577 · rdgdoc.xml · derivative · entry 1 Shah Vinay · CIK 0001753078 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2032-01-24 F1 · shares: These options vest pro rata on a monthly basis over four (4) years commencing on February 24, 2022, the one-month anniversary of the grant date. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over four (4) years commencing on February 24, 2022, the one-month anniversary of the grant date. Read SEC document |
| June 29, 2021 Filed Jun 29, 2021 23:36 UTC | Aravive, Inc. ARAV · Entity 114535 | PurchaseCommon Stock | 1,000 | $5.31 | $5,310.00 |
DisclosureSEC source: 0001437749-21-015968 · rdgdoc.xml · nonDerivative · entry 1 Shah Vinay · CIK 0001753078 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,842 Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 21:45 UTC | Aravive, Inc. ARAV · Entity 114535 | GrantStock Options · Derivative | 60,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0000899243-21-003306 · doc4.xml · derivative · entry 1 Shah Vinay · CIK 0001753078 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-01-24 F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over a four-year period commencing on February 25, 2021. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 01:05 UTC | Aravive, Inc. ARAV · Entity 114535 | PurchaseCommon Stock | 8,000 | $5.76 | $46,080.00 |
DisclosureSEC source: 0000899243-20-032920 · doc4.xml · nonDerivative · entry 1 Shah Vinay · CIK 0001753078 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,842 F1 · price: The price reported in column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $5.73 to $5.79, inclusive. The reporting person undertakes to provide Aravive, Inc., any security holder of Aravive, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote. F2 · balance_after: Includes an aggregate of 3,236 shares acquired under the Aravive, Inc. 2014 Employee Stock Purchase Plan, of which 416 shares were acquired on each of May 15, 2019, November 15, 2019 and May 15, 2020, respectively and 1,988 shares were acquired on November 13, 2020. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 21:13 UTC | Aravive, Inc. ARAV · Entity 114535 | GrantStock Option · Derivative | 34,826 | $0.00 Strike: $10.84 | $0.00 |
DisclosureSEC source: 0000899243-20-001969 · doc4.xml · derivative · entry 1 Shah Vinay · CIK 0001753078 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,826 Underlying: Common stock · 34,826 shares Expires 2030-01-21 F1 · shares: These options vest pro rata on a monthly basis over four (4) years commencing on the one month anniversary of the grant date. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over four (4) years commencing on the one month anniversary of the grant date. F1 · derivative.underlying_shares: These options vest pro rata on a monthly basis over four (4) years commencing on the one month anniversary of the grant date. F1 · balance_after: These options vest pro rata on a monthly basis over four (4) years commencing on the one month anniversary of the grant date. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:54 UTC | Aravive, Inc. ARAV · Entity 114535 | GrantStock Option · Derivative | 38,000 | $0.00 Strike: $5.83 | $0.00 |
DisclosureSEC source: 0000899243-19-005790 · doc4.xml · derivative · entry 1 Shah Vinay · CIK 0001753078 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2029-02-27 F1 · shares: These options vest pro rata on a monthly basis over 48 months. Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 22:19 UTC | Aravive, Inc. ARAV · Entity 114535 | GrantStock Option (Right to Buy) · Derivative | 19,000 | Not disclosed Strike: $0.90 | Not disclosed |
DisclosureSEC source: 0001209191-18-055185 · doc4.xml · derivative · entry 5 Shah Vinay · CIK 0001753078 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2028-03-20 F5 · price: On March 20, 2018, Reporting Person was granted an option to purchase 50,000 shares of the common stock of Aravive at an exercise price of $0.34 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 19,000 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.90 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger. F5 · derivative.exercise_date: On March 20, 2018, Reporting Person was granted an option to purchase 50,000 shares of the common stock of Aravive at an exercise price of $0.34 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 19,000 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.90 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger. Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 22:19 UTC | Aravive, Inc. ARAV · Entity 114535 | GrantStock Option (Right to Buy) · Derivative | 19,000 | Not disclosed Strike: $0.90 | Not disclosed |
DisclosureSEC source: 0001209191-18-055185 · doc4.xml · derivative · entry 4 Shah Vinay · CIK 0001753078 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2027-12-14 F4 · price: On December 14, 2017, Reporting Person was granted an option to purchase 50,000 shares of the common stock of Aravive at an exercise price of $0.34 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 19,000 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.90 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger. F4 · derivative.exercise_date: On December 14, 2017, Reporting Person was granted an option to purchase 50,000 shares of the common stock of Aravive at an exercise price of $0.34 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 19,000 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.90 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger. Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 22:19 UTC | Aravive, Inc. ARAV · Entity 114535 | GrantStock Option (Right to Buy) · Derivative | 38,001 | Not disclosed Strike: $0.66 | Not disclosed |
DisclosureSEC source: 0001209191-18-055185 · doc4.xml · derivative · entry 3 Shah Vinay · CIK 0001753078 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,001 Underlying: Common Stock · 38,001 shares Expires 2027-06-15 F3 · price: On June 15, 2017, Reporting Person was granted an option to purchase 100,000 shares of the common stock of Aravive at an exercise price of $0.23 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 38,001 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.66 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger. F3 · derivative.exercise_date: On June 15, 2017, Reporting Person was granted an option to purchase 100,000 shares of the common stock of Aravive at an exercise price of $0.23 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 38,001 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.66 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger. Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 22:19 UTC | Aravive, Inc. ARAV · Entity 114535 | GrantStock Option (Right to Buy) · Derivative | 19,380 | Not disclosed Strike: $0.24 | Not disclosed |
DisclosureSEC source: 0001209191-18-055185 · doc4.xml · derivative · entry 2 Shah Vinay · CIK 0001753078 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,380 Underlying: Common Stock · 19,380 shares Expires 2024-09-30 F2 · price: On October 1, 2014, Reporting Person was granted an option to purchase 51,000 shares of the common stock of Aravive at an exercise price of $0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 19,380 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger. F2 · derivative.exercise_date: On October 1, 2014, Reporting Person was granted an option to purchase 51,000 shares of the common stock of Aravive at an exercise price of $0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 19,380 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger. Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 22:19 UTC | Aravive, Inc. ARAV · Entity 114535 | GrantCommon Stock | 178,606 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-055185 · doc4.xml · nonDerivative · entry 1 Shah Vinay · CIK 0001753078 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,606 F1 · price: Shares of common stock of the corporation known as Aravive Biologics, Inc. ("Aravive") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of June 3, 2018, by and among the Issuer, Velo Merger Sub, Inc. and Aravive (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of Aravive common stock was exchanged for 2.2801 shares of the Issuer's common stock, subject to adjustment for any reverse stock split. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every six shares of Issuer common stock outstanding and the Issuer changed its name to Aravive, Inc. All share and option numbers reflect the reverse stock split. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.